We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Shoots Down Janssen’s Xarelto for ACS Indication
FDA Advisory Panel Shoots Down Janssen’s Xarelto for ACS Indication
May 25, 2012
An FDA advisory panel voted 6–4 Wednesday, with one abstention, against recommending approval of a new indication for Janssen’s oral anticoagulant Xarelto in patients with acute coronary syndrome (ACS).